FDA Approves VORICONAZOLE — Camber Pharmaceuticals, Inc.

The FDA on August 8, 2025, approved Voriconazole Oral Suspension (ANDA211598) from Camber Pharmaceuticals, Inc., positioning the company to capture significant market share in the antifungal space. This approval addresses a critical need for patient-friendly formulations and allows Camber to enter a competitive segment driven by rising demand for generic alternatives.